tschussman, you just need to hope that they don't go light again. They admitted last year that they should have run a trial EXACTLY LIKE TROFINETIDE. That is crazy, right? I mean they literally knew the trofinetide trial design before they ran their own trial. And they decided they were not sure whether 2-73 would work so they ran one that was 1/3 the size.
It is good that you were able to buy more cheaply after the stock cratered - but I would have preferred Rett was successful. I bet Rett patients' families also would have preferred that. And AD patients would have preferred that Anavex took a crowbar to its wallet and enrolled another 200 patients. Approvals would have already happened and patients would have been better off - and so would investors.
Market Data 
Markets 
AI
